<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer Policy</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer Policy</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of cancer policy</journal-title></journal-title-group><issn pub-type="epub">2213-5383</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7189771</article-id><article-id pub-id-type="pmcid-ver">PMC7189771.1</article-id><article-id pub-id-type="pmcaid">7189771</article-id><article-id pub-id-type="pmcaiid">7189771</article-id><article-id pub-id-type="manuscript-id">NIHMS1551682</article-id><article-id pub-id-type="pmid">32351875</article-id><article-id pub-id-type="doi">10.1016/j.jcpo.2020.100218</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1551682</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1551682</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Estimating cost implications of potentially avoidable hospitalizations among Oncology Care Model patients with prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="WH">William H.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parikh</surname><given-names initials="AB">Anish B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="L">Lihua</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanderson</surname><given-names initials="M">Mark</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mazumdar</surname><given-names initials="M">Madhu</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Isola</surname><given-names initials="LM">Luis M.</given-names></name><degrees>MD FACP</degrees><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dharmarajan</surname><given-names initials="KV">Kavita V.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A6">f</xref></contrib></contrib-group><aff id="A1"><label>a.</label>Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A2"><label>b.</label>Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, OH, USA</aff><aff id="A3"><label>c.</label>Institute of Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A4"><label>d.</label>Department of Health System Design and Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A5"><label>e.</label>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A6"><label>f.</label>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding Author</bold>: Kavita V. Dharmarajan, MD, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Dept of Radiation Oncology, Box 1236, New York, NY 10029, (P): 212-241-7500, <email>kavita.dharmarajan@mountsinai.org</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P33">Conflicts of Interest Statement</p><p id="P34">Mark Liu has received honoraria from Bristol-Myers Squib. The remaining authors of this study certify that they have no affiliation or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter discussed in this manuscript.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2020</year></pub-date><volume>23</volume><issue-id pub-id-type="pmc-issue-id">356713</issue-id><elocation-id>100218</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>04</day><month>02</month><year>2020</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-14 06:25:47.830"><day>14</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1551682.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.sciencedirect.com/science/article/pii/S2213538319301006?via%3Dihub"/><abstract id="ABS1"><sec id="S1"><title>Purpose/Objectives:</title><p id="P1">We sought to estimate the expected cost savings generated if a set of potentially avoidable hospitalizations (PAHs) among oncology care model (OCM) patients with prostate cancer were shifted to an acute care model in the outpatient setting.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">We previously identified a set of 28 PAHs among OCM prostate cancer patients. Outpatient management costs for a characteristically similar cohort of cancer patients were obtained from our institution&#8217;s ambulatory acute-care Oncology Care Unit (OCU). We excluded OCU visits resulting in hospitalization, involving non-cancer diagnoses, and those missing clinical/financial information. Exact-matching based on the strata of age, categorically-defined presenting complaint, and systemic disease was used to match PAHs to OCU acute care visits. PAH costs obtained from OCM data were compared to costs from matched OCU visits.</p></sec><sec id="S3"><title>Results:</title><p id="P3">We identified 130 acute care OCU visits, of which 47 met inclusion criteria. Twenty-four PAHs (89%) matched to 26 of these OCU visits. PAHs accounted for 5.8% of OCM expenditures during our study period. The mean inpatient cost among matched PAHs was $15,885 compared to $6,227 for matched OCU visits. Boot strapping within each match stratum produced a mean estimated cost savings of $12,151 (95% CI $10,488 to $13,814) per PAH. We estimate this per event savings to yield a 4.4% (95% CI 3.8% to 5.0%) an overall spending decrement for OCM prostate cancer episodes.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">PAHs contribute meaningfully to costs of care in oncology. Investment in specialized ambulatory acute care services for oncology patients could lead to substantial cost savings.</p></sec></abstract><kwd-group><kwd>Potentially avoidable hospitalizations</kwd><kwd>Oncology Care Model</kwd><kwd>Value-based healthcare</kwd><kwd>Prostate cancer outcomes</kwd><kwd>Acute oncology care</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>